Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage

Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients

Zhixiang Shen, Guoqiang Chen, Jian-Hua Ni et al. · Blood · 1997 · 1.4K citations

Medicine, Pharmacokinetics, Pharmacology +17

Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide

Steven L. Soignet, P. Maslak, Zhugang Wang et al. · New England Journal of Medicine · 1998 · 1.2K citations

Medicine, Hematology, Pharmacology +9

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins

G-Q Chen, Jing Zhu, XG Shi et al. · Blood · 1996 · 852 citations · Full text

Life Sciences, Cell Biology, Oncology +16

Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.

Guoqiang Chen, Xuegeng Shi, Wei Tang et al. · PubMed · 1997 · 803 citations

Medicine, Hematology, Oncology +14

Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia Patients

Chao Niu, Hua Yan, Ting Yu et al. · Blood · 1999 · 627 citations

Medicine, Hematology, Oncology +17